RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia - PubMed (original) (raw)
. 2006 Jan 10;103(2):466-71.
doi: 10.1073/pnas.0502090103. Epub 2006 Jan 3.
Martine Schmitt, Jean-Paul Laulin, Emilie Laboureyras, Jack H Jhamandas, David MacTavish, Audrey Matifas, Catherine Mollereau, Patrick Laurent, Marc Parmentier, Brigitte L Kieffer, Jean-Jacques Bourguignon, Guy Simonnet
Affiliations
- PMID: 16407169
- PMCID: PMC1326150
- DOI: 10.1073/pnas.0502090103
RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia
Frédéric Simonin et al. Proc Natl Acad Sci U S A. 2006.
Erratum in
- Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16058
Abstract
Neuropeptide FF (NPFF) has been proposed to play a role in pain modulation, opioid tolerance, and several other physiological processes. However, pharmacological agents that would help define physiological roles for this peptide are still missing. Here we report the discovery of a potent and selective NPFF receptor antagonist, RF9, that can be administered systemically. This compound does not show any effects by itself but can block efficiently the increase in blood pressure and heart rate evoked by NPFF. When chronically coinjected with heroin, RF9 completely blocks the delayed and long-lasting paradoxical opioid-induced hyperalgesia and prevents the development of associated tolerance. Our data indicate that NPFF receptors are part of a bona fide antiopioid system and that selective antagonists of these receptors could represent useful therapeutic agents for improving the efficacy of opioids in chronic pain treatment.
Figures
Fig. 1.
Screening of RFamide derivatives on hNPFF2R. (A) hNPFF2R membranes were labeled with [125I]Tyr-NPFF, and three concentrations of RFamide derivatives were tested in competition experiments. Each concentration was tested in duplicate. Results for the reference and the six most active compounds are shown. Arrowheads indicate compounds that were selected for further characterization. (B) Structures of RF2, RF9, RF48, RF49, and BIBP3226.
Fig. 2.
In vitro characterization of compounds selected from the screening. (A) Stimulation of [35S]GTPγS binding to hNPFF2R by NPFF (▪), RF2 (▴), RF48 (▾) and RF49 (♦). (B) Stimulation of [35S]GTPγS binding to hNPFF2R by NPFF alone (▪) or NPFF in presence of 7.5 μM RF9 (▴). RF9 shifted the concentration-effect curve of NPFF to the right by ≈160-fold. Data are expressed as percentage of basal [35S]GTPγS binding and represent mean ± SE from at least two separate experiments in triplicate. (C) RF9 (black bars) reversed the inhibition of forskolin-induced cAMP by NPVF in CHO-hNPFF1R cells. RF9 alone was inactive, whereas NPVF (white bar) inhibited ≈60% of the stimulated cAMP. Error bars represent the mean ± SEM of data from three experiments performed in duplicate.
Fig. 3.
RF9 blocks blood pressure effects of NPFF. (A) Changes in MAP [expressed in mmHg (1 mmHg = 133 Pa)] in rats receiving either i.c.v. saline (♦), NPFF (▪), RF9 (×), or NPFF and RF9 applied together (▴). Time 0 indicates the injection point for i.c.v. saline or drug applications. (B) Heart rate changes that accompany MAP alterations in A. Pooled MAP and heart rate data are from five animals. *, significant difference in MAP or heart rate compared with control (P < 0.05).
Fig. 4.
Coadministration of RF9 with heroin prevents heroin-induced delayed hyperalgesia and tolerance. (A) Delayed effects of 14 once-daily coadministrations of saline or RF9 (0.1 mg/kg, s.c.) 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats (n = 8 rats per group). The basal nociceptive threshold was determined once daily 60 min before each heroin or saline administration and after the heroin treatment was stopped. When rats in the saline/heroin group had recovered their predrug nociceptive threshold (D28), changes in nociceptive threshold induced by 0.3 mg/kg heroin in the saline/heroin and RF9/heroin groups were estimated for several days. Mean paw-pressure values for triggering vocalization (±SEM) are expressed in grams. #, P < 0.05 with a Newman-Keuls test when the RF9/heroin and saline/heroin groups were compared. (B) Analgesic effect induced by 0.3 mg/kg heroin (or saline) in the saline/saline (○), RF9/saline (•), saline/heroin (⋄), and RF9/heroin (♦) groups on D1,D14, and D28 (n = 8 rats per group). The nociceptive threshold of animals was measured 30 min after heroin injection and then every 30 min until the end of the pharmacological effect. (Inset) Comparison of AUC. Mean paw-pressure values for triggering vocalization (±SEM) are expressed in grams. *, P < 0.05 with Dunnett's test as compared with basal nociceptive value; #, P < 0.05 with a Newman-Keuls test comparing the RF9/heroin group with the saline/heroin group.
Similar articles
- Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
Elhabazi K, Trigo JM, Mollereau C, Moulédous L, Zajac JM, Bihel F, Schmitt M, Bourguignon JJ, Meziane H, Petit-demoulière B, Bockel F, Maldonado R, Simonin F. Elhabazi K, et al. Br J Pharmacol. 2012 Jan;165(2):424-35. doi: 10.1111/j.1476-5381.2011.01563.x. Br J Pharmacol. 2012. PMID: 21718302 Free PMC article. - Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist.
Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R. Fang Q, et al. Regul Pept. 2008 Apr 10;147(1-3):45-51. doi: 10.1016/j.regpep.2007.12.007. Epub 2008 Jan 11. Regul Pept. 2008. PMID: 18276024 - [RF9, a powerful and selective antagonist of the neuropeptide FF receptors, prevents the development of the tolerance to opioids].
Bourguignon JJ, Simonnet G, Simonin F. Bourguignon JJ, et al. Med Sci (Paris). 2006 Jun-Jul;22(6-7):579-80. doi: 10.1051/medsci/20062267579. Med Sci (Paris). 2006. PMID: 16828031 French. No abstract available. - Opioid hyperalgesia and tolerance versus 5-HT1A receptor-mediated inverse tolerance.
Xu XJ, Colpaert F, Wiesenfeld-Hallin Z. Xu XJ, et al. Trends Pharmacol Sci. 2003 Dec;24(12):634-9. doi: 10.1016/j.tips.2003.10.005. Trends Pharmacol Sci. 2003. PMID: 14654304 Review. - Opioid induced hyperalgesia: clinical implications for the pain practitioner.
Silverman SM. Silverman SM. Pain Physician. 2009 May-Jun;12(3):679-84. Pain Physician. 2009. PMID: 19461836 Review.
Cited by
- Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure.
Lee H, Amatya B, Villar VAM, Asico LD, Jeong JK, Feranil J, Moore SC, Zheng X, Bishop M, Gomes JP, Polzin J, Smeriglio N, de Castro PASV, Armando I, Felder RA, Hao L, Jose PA. Lee H, et al. Sci Rep. 2024 Jul 4;14(1):15407. doi: 10.1038/s41598-024-64484-9. Sci Rep. 2024. PMID: 38965251 Free PMC article. - Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides.
Strnadová V, Pačesová A, Charvát V, Šmotková Z, Železná B, Kuneš J, Maletínská L. Strnadová V, et al. Biosci Rep. 2024 Apr 24;44(4):BSR20231385. doi: 10.1042/BSR20231385. Biosci Rep. 2024. PMID: 38577975 Free PMC article. Review. - Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction.
Hu KL, Chen Z, Li X, Cai E, Yang H, Chen Y, Wang C, Ju L, Deng W, Mu L. Hu KL, et al. Reprod Biol Endocrinol. 2022 May 23;20(1):81. doi: 10.1186/s12958-022-00953-y. Reprod Biol Endocrinol. 2022. PMID: 35606759 Free PMC article. Review. - Neuropeptide FF-related gene in fish (Larimichthys polyactis): identification, characterization, and potential anti-inflammatory function.
Xiao R, Guo Z, Zheng LB, Huang W, Chi CF, Lou B. Xiao R, et al. Mol Biol Rep. 2022 Jul;49(7):6385-6394. doi: 10.1007/s11033-022-07447-5. Epub 2022 May 3. Mol Biol Rep. 2022. PMID: 35503491 - Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect.
Alexopoulou F, Bech EM, Pedersen SL, Thorbek DD, Leurs U, Rudkjær LCB, Fosgerau K, Hansen HH, Vrang N, Jelsing J, Elster L. Alexopoulou F, et al. Sci Rep. 2022 Feb 1;12(1):1696. doi: 10.1038/s41598-022-05310-y. Sci Rep. 2022. PMID: 35105898 Free PMC article.
References
- Roumy, M. & Zajac, J. M. (1998) Eur. J. Pharmacol. 345, 1-11. - PubMed
- Zajac, J. M. (2001) Trends Pharmacol. Sci. 22, 63. - PubMed
- Bonini, J. A., Jones, K. A., Adham, N., Forray, C., Artymyshyn, R., Durkin, M. M., Smith, K. E., Tamm, J. A., Boteju, L. W., Lakhlani, P. P., et al. (2000) J. Biol. Chem. 275, 39324-39331. - PubMed
- Hinuma, S., Shintani, Y., Fukusumi, S., Iijima, N., Matsumoto, Y., Hosoya, M., Fujii, R., Watanabe, T., Kikuchi, K., Terao, Y., et al. (2000) Nat. Cell Biol. 2, 703-708. - PubMed
- Liu, Q., Guan, X. M., Martin, W. J., McDonald, T. P., Clements, M. K., Jiang, Q., Zeng, Z., Jacobson, M., Williams, D. L., Jr., Yu, H., et al. (2001) J. Biol. Chem. 276, 36961-36969. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases